Responding to a small-scale bioterrorist anthrax attack: Cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination

Archives of Internal Medicine

Volumn 167, Issue 7, 2007, Pages 655-662

  Schmitt, Brian ^a,b,f   Dobrez, Deborah ^c   Parada, Jorge P ^b   Kyriacou, Demetrios N ^d   Golub, Robert M ^e   Sharma, Rishi ^a   Bennett, Charles ^a,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIBIOTIC AGENT; CIPROFLOXACIN;

ANTHRAX; ANTIBIOTIC THERAPY; ARTICLE; BIOLOGICAL WARFARE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISASTER; DISASTER PLANNING; DRUG COST; EXPOSURE; HUMAN; MONTE CARLO METHOD; POSTAL MAIL; PRIORITY JOURNAL; PROPHYLAXIS; SENSITIVITY ANALYSIS; UNITED STATES; UNSPECIFIED SIDE EFFECT; VACCINATION;

ANTHRAX; ANTHRAX VACCINES; ANTI-BACTERIAL AGENTS; BIOTERRORISM; COST-BENEFIT ANALYSIS; EMERGENCY MEDICAL SERVICES; HUMANS;

EID: 34247160375     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.7.655     Document Type: Article

References (45)

1. Centers for Disease Control and Prevention. Update: investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep. 2001;50:889-893.
2. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep. 2001;50:909-919.
3. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep. 2001;50:941-948.
4. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. MMWR Morb Mortal Wkly Rep. 2001;50:973-976.
5. Centers for Disease Control and Prevention. Considerations for distinguishing influenzalike illness from inhalational anthrax. MMWR Morb Mortal Wkly Rep. 2001;50:984-986.
6. Barakat LA, Quentzel HL, Jernigan JA, et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA. 2002;287:863-868.
7. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis. 2001;7:933-944.
8. Reissman DB, Whitney EA, Taylor TH Jr, et al. One-year health assessment of adult survivors of Bacillus anthracis infection. JAMA. 2004;291:1994-1998.
9. Brookmeyer R, Johnson E, Bollinger R. Public health vaccination policies for containing an anthrax outbreak. Nature. 2004;432:901-904.
10. Wein LM, Craft DL, Kaplan EH. Emergency response to an anthrax attack. Proc Natl Acad Sci U S A. 2003;100:4346-4351.
11. Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis. 2002;8:1124-1132.
12. Wein LM, Craft DL; Anthrax Modeling Working Group. Evaluation of public health interventions for anthrax: a report to the Secretary's Council on Public Health Preparedness. Biosecur Bioterror. 2005;3:348-356.
13. Braithwaite RS, Fridsma D, Roberts MS. The cost-effectiveness of strategies to reduce mortality from an intentional release of aerosolized anthrax spores. Med Decis Making. 2006;26:182-193.
14. Schneider H. Protecting public health in the age of bioterrorism surveillance: is the price right? J Environ Health. 2005;68:9-13.
15. Fowler RA, Sanders GD, Bravata DM, et al. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med. 2005;142:601-610.
16. Meehan PJ, Rosenstein NE, Gillen M, et al. Responding to detection of aerosolized Bacillus anthracis by autonomous detection systems in the workplace.MMWR Recomm Rep. 2004;53:1-12.
17. Gold M, Sigel J, Russell L, Weinstein M, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
18. Annual Report of the US Postal Service. Washington, DC: Government Printing Office; 2004.
19. Cymet TC, Kerkvliet GJ. What is the true number of victims of the postal anthrax attack of 2001? [letter]. J Am Osteopath Assoc. 2004;104:452.
20. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management [published correction appears in JAMA. 2002;288:1849]. JAMA. 2002;287:2236-2252.
21. Geier MR, Geier DA. Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Hepatogastroenterology. 2004;51:762-767.
22. Enstone JE, Wale MC, Nguyen-Van-Tam JS, Pearson JC. Adverse medical events in British service personnel following anthrax vaccination. Vaccine. 2003;21:1348-1354.
23. Hoffman K, Costello C, Menich M, Grabenstein JD, Engler RJ. Using a structured medical note for determining the safety profile of anthrax vaccine for US soldiers in Korea. Vaccine. 2003;21:4399-4409.
24. Centers for Disease Control and Prevention. Surveillance for adverse events associated with anthrax vaccination: US Department of Defense, 1998-2000.MMWR Morb Mortal Wkly Rep. 2000;49:341-345.
25. Tierney BC, Martin SW, Franzke LH, et al. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorismrelated inhalational anthrax. Clin Infect Dis. 2003;37:905-911.
26. Friedlander AM, Pittman PR, Parker GW. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA. 1999;282:2104-2106.
27. Wright GG, Green TW, Kanode RG Jr. Studies on immunity in anthrax, V: immunizing activity of alum-precipitated protective antigen. J Immunol. 1954;73:387-391.
28. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond). 1956;54:28-36.
29. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583-637.
30. HHS buys anthrax vaccine for civilian stockpile [press release]. Minneapolis: Center for Infectious Disease Research & Policy, Academic Health Center, University of Minnesota; May 5, 2005. http://www.cidrap.umn.edu/ cidrap/content/bt/anthrax/news/may0605anthrax.html. Accessed June 15, 2005.
31. American Medical Association. Current Procedural Terminology. https://catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp. Accessed February 6, 2006.
32. Fleming T, ed. Drug Topics Red Book. Montvale, NJ: Thomson PDR; 2005.
33. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project. http://hcup.ahrq.gov/HCUPnet.asp. Accessed February 6, 2006.
34. Pitt ML, Little S, Ivins BE, et al. In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol. 1999;87:304.
35. Ivins BE, Fellows P, Pitt ML, et al. Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Med Bull. 1996;87:125-126.
36. Fellows PF, Linscott MK, Ivins BE, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin [published correction appears in Vaccine. 2001;20:635]. Vaccine. 2001;19:3241-3247.
37. Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993;167:1239-1243.
38. Altboum Z, Gozes Y, Barnea A, Pass A, White M, Kobiler D. Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect Immun. 2002;70:6231-6241.
39. Brachman P, Gold H, Plotkin S, Fekety F, Werrin M, Ingraham N. Field evaluation of a human anthrax vaccine. Am J Public Health. 1962;52:632-645.
40. Greene CM, Reefhuis J, Tan C, et al. Epidemiologic investigations of bioterrorismrelated anthrax, New Jersey, 2001. Emerg Infect Dis. 2002;8:1048-1055.
41. Dewan PK, Fry AM, Laserson K, et al. Inhalational anthrax outbreak among postal workers, Washington, DC, 2001. Emerg Infect Dis. 2002;8:1066-1072.
42. Mandell G, Bennett J, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. New York, NY: Churchill Livingstone; 2000.
43. Brachman P, Kaufman A. Anthrax. In: Evans A, Brachman P, eds. Bacterial Infections of Humans. New York, NY: Plenum Medical Book Co; 1998:95-111.
44. Bureau of Labor Statistics. Archived Consumer Price Index News Releases. http://www.bls.gov/cpi/home.htm#data. Accessed March 13, 2005.
45. Brookmeyer R, Johnson E, Bollinger R. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Natl Acad Sci U S A. 2003;100:10129-10132.